Aqueous Humor and Tear Biomarkers: July 2026 Omics Updates

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/aqueous-humor-and-tear-biomarkers-july-2026-omics-updates

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Introduction Glaucoma, a leading cause of irreversible vision loss, can be hard to detect early. Researchers are now looking at biomarkers in the eye’s body fluids – the aqueous humor (the fluid inside the front of the eye) and tear fluid (the film covering the eye) – to find signs of disease. New “omics” technologies (advanced protein and metabolite profiling) allow scientists to take a detailed molecular snapshot of these fluids. Recent studies (June–July 2026) have identified candidate markers in tears and aqueous humor that might help in diagnosing glaucoma or predicting its progression () (). In this update, we summarize the latest findings on tears and aqueous humor, describe how these studies were done, and discuss what it will take to turn these discoveries into real clinical tests. Tear Fluid Biomarkers Tear fluid is easy to collect (for example, by capillary tubes or filter paper), making it an attractive source of markers. Modern proteomic methods (mass spectrometry) can detect dozens of proteins in a tiny tear sample. A recent tear proteomics study of normal-tension glaucoma (a form of glaucoma with normal eye pressure) found 15 proteins that differed in patients whose visual fields were worsening (). For example, they identified the antioxidant protein peroxiredoxin-4 (PRDX4) and other proteins linked to oxidative stress. One protein, GNAI1, gave a high diagnostic score (AUC≈0.89) in distinguishing rapid progressors from slow progressors (). This suggests tear proteins may predict disease progression (prognostic use) rather than just presence of disease. Another study (in Eye Discovery, June 2026) looked across several glaucoma types and tear compositions, finding unique patterns for each subtype. These preliminary results hint that tear markers might eventually help subtype glaucoma or monitor changes, but they need confirmation. Sampling methods matter. Tears can be collected by Schirmer strips or capillary tubes, and these methods give slightly different results – for example, capillary collection is less irritating and preserves more tear proteins (). Such technical details can affect reproducibility, so it’s important to standardize collection when comparing studies. Overall, tear studies show promise. They have identified candidate biomarkers (linked to oxidative stress and inflammation) () (). But most findings are so far from small groups of patients. Larger validation studies are needed before any tear test could be used in the clinic (). Aqueous Humor Biomarkers The aqueous humor is the clear fluid bathing the front of the eye. It is obtained during procedures like cataract or glaucoma surgery. Because volumes are small, each sample is precious. Recent studies have profiled its content to find glaucoma clues: Protein and EV profiling: One work used label-free proteomics to map the protein “portraits” of aqueous humor in two common glaucoma types (primary open-angle and pseudoexfoliation glaucoma) (). They found many proteins that differed by disease type. (This study is under peer review but highlights how mass spectrometry can reveal glaucoma-specific protein changes.) Exosomal miRNA: Tiny vesicles called extracellular vesicles (exosomes) carry microRNAs (miRNAs) that regulate genes. A recent pilot study sequenced miRNAs from aqueous humor–derived exosomes in two glaucoma forms. It found, for example, that miR-451a was higher in primary open-angle glaucoma and miR-26a-5p higher in exfoliation glaucoma, while the anti-scarring miR-29a-3p was down in both types (). These miRNAs target extracellular-matrix and fibrotic pathways. As the authors note, this “first profile” of AH exosomal miRNAs highlights potential biomarkers (and even therapeutic targets) for glaucoma (). In lab tests, boosting miR-29a-3p reduced fibrotic changes in eye cells, hinting at a disease link (). Spectral fingerprinting of exosomes: A novel diagnostic approach used surface-enhanced Raman spectroscopy on antibodies that captured AH exosomes. An AI model then classified spectra from glaucoma vs control samples. Impressively, this method achieved ~91% accuracy (AUC=0.96) in distinguishing glaucoma patients (). It shows that even without identifying individual molecules, complex spectral patterns from AH exosomes can serve as diagnostic signatures. Metabolites and lipids: Metabolomic studies (measuring small molecules) have yielded clues too. A recent lipidomic analysis found that glaucoma patients had significantly higher levels of lipoxin A4 (an anti-inflammatory lipid) and its precursor arachidonic acid in their aqueous humor (). This was traced to glaucoma medications: for example, the common drug latanoprost was shown to induce lipoxin production in eye tissues () (). These findings suggest that conventional treatment alters lipid pathways, which now emerge as glaucoma “signatures.” In sum, AH studies are uncovering both molecular markers (specific proteins, miRNAs, lipids) and patterns that differ in glaucoma. Many of the identified changes point to disease pathways (see below). Diagnostic vs. Prognostic Utility and Reproducibility A key question is whether a marker indicates glaucoma is present now (diagnostic) or predicts what happens next (prognostic). In tears, the NTG study was aimed at progression (prognosis) (). In contrast, the AH exosome Raman study was purely diagnostic (glaucoma vs healthy) (). The exosomal miRNA pilot also focused on subtype diagnosis (). Most discovery studies to date are diagnostic in nature. However, none of these putative biomarkers is ready for clinical use. As one review notes, despite identifying many candidates tied to oxidative stress, inflammation or vascular dysfunction, no molecular biomarker has yet been validated for routine glaucoma diagnosis () (). Reproducibility remains a challenge: different labs use different tear collection methods, protein assays, and analytical platforms (). Even aqueous humor studies are small and usually single-center. Validation cohorts (independent patient groups) are rare. For example, the tear proteomics report did not test its biomarkers in a separate population; it only used statistical analysis on the study group (). Thus, while these findings are encouraging, they should be viewed as early leads. Larger-scale studies are required to confirm whether the same markers emerge in other patients and to rule out false positives. In practice, a combination of several markers (a signature panel) might be needed to reach high accuracy. Rigorous standardization of sample handling and analysis will be essential to make results reproducible across clinics. Pathway Enrichment and Biological Insights Beyond individual molecules, researchers look for common pathways that glaucoma targets. Many of the differing molecules fall into a few themes: oxidative stress, inflammation, and extracellular matrix (ECM) remodeling (). For instance, PRDX4 in tears is an antioxidant enzyme, and the AH miRNA results involved ECM-related miRNAs (). Metabolomic analyses reinforce these ideas. A recent meta-analysis pooling data from multiple studies found that pathways involving arginine and proline metabolism were consistently altered in glaucoma – in both aqueous humor and blood (). Arginine/proline metabolism is linked to oxidative stress and neurodegeneration, suggesting these processes play a central role (). The lipoxin study highlighted the arachidonic acid–lipoxin pathway. Lipoxin A4 is a natural anti-inflammatory mediator. Its elevation in glaucoma patients’ AH (likely driven by eye-drop medications) suggests a drug-induced anti-inflammatory response () (). This ties into broader evidence that resolving inflammation may be neuroprotective in glaucoma. In summary, pathway analyses of the new biomarkers point to known glaucoma mechanisms (oxidative damage, immune signaling, wound healing in the eye) () (). These insights help explain why certain markers change and can guide future targets for therapy or monitoring. Steps Toward Clinical Translation Turning these omics findings into a useful clinical test will require many steps. First, candidate markers must be confirmed in larger, independent cohorts. Studies should include diverse populations and controls (e.g. cataract patients) to ensure specificity to glaucoma. Multicenter trials would help establish consistency. Second, a practical assay must be developed. This likely means moving from broad discovery (mass spec, sequencing) to targeted tests. For example, a few key proteins or miRNAs could be measured by antibody-based tests or PCR assays. Any exosome-based test needs a simple way to isolate them (commercial kits) and robust readout (like a Raman sensor or PCR panel). These assays must be optimized for speed, cost, and reproducibility. Regulatory validation will involve defining clear cut-off values, testing sensitivity/specificity in the real world, and comparing with standard glaucoma exams. In the case of tears, methods to collect and store the fluid must be standardized across clinics (). The powerful AI-based exosome classifier () illustrates what is technically possible, but to become a routine test it would need to be replicated (e.g. with blinded new samples) and automated into a user-fri

Transcript

SPEAKER_00 0:00

Introduction. Glaucoma, a leading cause of irreversible vision loss, can be hard to detect early. Researchers are now looking at biomarkers in the eye's body fluids, the aqueous humor, the fluid inside the front of the eye, and tear fluid, the film covering the eye, to find signs of disease. New omics technologies, advanced protein and metabolite profiling, allow scientists to take a detailed molecular snapshot of these fluids. Recent studies, June-July 2026, have identified candidate markers in tears and aqueous humor that might help in diagnosing glaucoma or predicting its progression. In this update, we summarize the latest findings on tears and aqueous humor, describe how these studies were done, and discuss what it will take to turn these discoveries into real clinical tests. Tear Fluid Biomarkers. Tear fluid is easy to collect, for example by capillary tubes or filter paper, making it an attractive source of markers. Modern proteomic methods, mass spectrometry, can detect dozens of proteins in a tiny tear sample. A recent tear proteomics study of normal tension glaucoma, a form of glaucoma with normal eye pressure, found 15 proteins that differed in patients whose visual fields were worsening. For example, they identified the antioxidant protein peroxyredoxin-4, PRDX4, and other proteins linked to oxidative stress. One protein, GNA1, gave a high diagnostic score, AUC0.89, in distinguishing rapid progressors from slow progressors. This suggests tear proteins may predict disease progression, prognostic use, rather than just presence of disease. Another study in Eye Discovery, June 2026, looked across several glaucoma types and tear compositions, finding unique patterns for each subtype. These preliminary results hint that tear markers might eventually help subtype glaucoma or monitor changes, but they need confirmation. Sampling methods matter. Tears can be collected by schermer strips or capillary tubes, and these methods give slightly different results. For example, capillary collection is less irritating and preserves more tear proteins. Such technical details can affect reproducibility, so it's important to standardize collection when comparing studies. Overall, tear studies show promise. They have identified candidate biomarkers linked to oxidative stress and inflammation, but most findings are so far from small groups of patients. Larger validation studies are needed before any tear test could be used in the clinic. Aqueous humor biomarkers. The aqueous humor is the clear fluid bathing the front of the eye. It is obtained during procedures like cataract or glaucoma surgery. Because volumes are small, each sample is precious. Recent studies have profiled its content to find glaucoma clues. Protein and EV profiling. One work used label-free proteomics to map the protein portraits of aqueous humor in two common glaucoma types, primary open angle and pseudo-exfoliation glaucoma. They found many proteins that differed by disease type. This study is under peer review but highlights how mass spectrometry can reveal glaucoma-specific protein changes. Exosomal mIRNA, tiny vesicles called extracellular vesicles, exosomes, carry microRNAs, mIRNAs, that regulate genes. A recent pilot study sequenced IRNAs from aqueous humor-derived exosomes in two glaucoma forms. It found, for example, that MyR451A was higher in primary open-angle glaucoma and myR26A5P higher in exfoliation glaucoma, while the anti-scarring MyR-29A3P was down in both types. These MIRNAs target extracellular matrix and fibrotic pathways. As the authors note, this first profile of AH exosomal MIRNAs highlights potential biomarkers and even therapeutic targets for glaucoma. In lab tests, boosting MIR-29A3P reduced fibrotic changes in eye cells, hinting at a disease link. Spectral fingerprinting of exosomes, a novel diagnostic approach, used surface-enhanced Raman spectroscopy on antibodies that captured AH exosomes. An AI model then classified spectra from glaucoma versus control samples. Impressively, this method achieved 91% accuracy, AUC equals 0.96, in distinguishing glaucoma patients. It shows that even without identifying individual molecules, complex spectral patterns from AH exosomes can serve as diagnostic signatures. Metabolites and lipids, metabolomic studies measuring small molecules, have yielded clues too. A recent lipidomic analysis found that glaucoma patients had significantly higher levels of lipoxin A4, an anti-inflammatory lipid, and its precursor arachidonic acid in their aqueous humor. This was traced to glaucoma medications. For example, the common drug Latanoprost was shown to induce lipoxin production in eye tissues. These findings suggest that conventional treatment alters lipid pathways, which now emerge as glaucoma signatures. In sum, AH studies are uncovering both molecular markers, specific proteins, myRNAs, lipids, and patterns that differ in glaucoma. Many of the identified changes point to disease pathways, see below. Diagnostic versus prognostic utility and reproducibility. A key question is whether a marker indicates glaucoma is present now, diagnostic, or predicts what happens next, prognostic. In tiers, the NTG study was aimed at progression, prognosis. In contrast, the AH exosome Raman study was purely diagnostic glaucoma versus healthy. The exosomal myRNA pilot also focused on subtype diagnosis. Most discovery studies to date are diagnostic in nature. However, none of these putative biomarkers is ready for clinical use. As one review notes, despite identifying many candidates tied to oxidative stress, inflammation, or vascular dysfunction, no molecular biomarker has yet been validated for routine glaucoma diagnosis. Reproducibility remains a challenge. Different labs use different tear collection methods, protein assays, and analytical platforms. Even aqueous humor studies are small and usually single-centered. Validation cohorts, independent patient groups are rare. For example, the tear proteomics report did not test its biomarkers in a separate population. It only used statistical analysis on the study group. Thus, while these findings are encouraging, they should be viewed as early leads. Larger scale studies are required to confirm whether the same markers emerge in other patients and to rule out false positives. In practice, a combination of several markers, a signature panel, might be needed to reach high accuracy. Rigorous standardization of sample handling and analysis will be essential to make results reproducible across clinics. Pathway enrichment and biological insights. Beyond individual molecules, researchers look for common pathways that glaucoma targets. Many of the differing molecules fall into a few themes: oxidative stress, inflammation, and extracellular matrix, ECM remodeling. For instance, PRDX4 in tears is an antioxidant enzyme, and the AH myRNA results involved ECM-related myRNAs. Metabolomic analyses reinforce these ideas. A recent meta-analysis pooling data from multiple studies found that pathways involving arginine and proline metabolism were consistently altered in glaucoma, in both aqueous humor and blood. Arginine-proline metabolism is linked to oxidative stress and neurodegeneration, suggesting these processes play a central role. The lipoxin study highlighted the arachidonic acid lipoxin pathway. Lipoxin A4 is a natural anti-inflammatory mediator. Its elevation in glaucoma patients' AH, likely driven by eyedrop medications, suggests a drug-induced anti-inflammatory response. This ties into broader evidence that resolving inflammation may be neuroprotective in glaucoma. In summary, pathway analyses of the new biomarkers point to known glaucoma mechanisms, oxidative damage, immune signaling, wound healing in the eye. These insights help explain why certain markers change and can guide future targets for therapy or monitoring. Steps toward clinical translation. Turning these OMIX findings into a useful clinical test will require many steps. First, candidate markers must be confirmed in larger, independent cohorts. Studies should include diverse populations and controls, e.g., cataract patients, to ensure specificity to glaucoma. Multicenter trials would help establish consistency. Second, a practical assay must be developed. This likely means moving from broad discovery, mass spec, sequencing to targeted tests. For example, a few key proteins or mIRNAs could be measured by antibody-based tests or PCR assays. Any exosome-based test needs a simple way to isolate them, commercial kits, and robust readout, like a Raman sensor or PCR panel. These assays must be optimized for speed, cost, and reproducibility. Regulatory validation will involve defining clear cutoff values, testing sensitivity specificity in the real world, and comparing with standard glaucoma exams. In the case of TIERS, methods to collect and store the fluid must be standardized across clinics. The powerful AI-based exosome classifier illustrates what is technically possible, but to become a routine test, it would need to be replicated, e.g., with blinded new samples, and automated into a user-friendly device or software. Experts emphasize that we are still at the discovery stage. As the authors of a Plasma EV study concluded, integrated molecular analyses are promising, groundwork for future non-invasive diagnostics. But they also point out the need to bridge basic discovery and clinical application. In practice, researchers will need to build such a bridge step by step, rigorous validation studies, development of standardized kits or point-of-care devices, and ultimately regulatory approval. Conclusion: The July 2026 OMIX updates show growing activity in mining eye fluids for glaucoma biomarkers. Proteomic and metabolomic profiling of tears and aqueous humor have highlighted new molecules and pathways, from tear proteins like PRDX4 to cataract AH lipids like lipoxin A4. Advanced techniques even hint that we might diagnose glaucoma by spectral fingerprints of exosomes. Yet for now, these findings remain preliminary. No tears or AH-based test has entered routine practice. Each candidate marker needs further testing in larger patient groups and translation into a simple assay. For patients, this means caution. There are no new eye drop or clinic tests yet. The standard pressure checks and vision tests still rain, but these laboratory advances could lead to future improvements. In the coming years, we may see tests that use a drop of tear fluid or a tiny sample of eye fluid to help diagnose glaucoma earlier or predict its course. The 2026 studies provide a roadmap of promising targets and pathways, as long as researchers follow through with the rigorous validation and assay development needed for clinical use. All links to sources are available in the text version of this article. You can find the full article at visualfieldtest.com. Thanks for listening. To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.